Biotechnology Industry in India

• Overview

• Scope

• Career Opportunities

• List of Top Companies

• Other Biotech Companies

• Recent Developments

General Introduction of Biotech Sector

Today the global biotech industry has nearly 1500
companies giving employment to over 1,79,000 people in
the fields of manufacturing, sales, research, development
and various other related jobs. The Indian biotech industry
is expected to grow up to Rs. 4,40,000 crores by 2020.
Pie chart showing the market share of key biotech
services in India
 International
International Top Indian Biotech
Biotech Companies
Biotech Companies Companies
in India
Genentech Inc. Biocon Monsanto
Shantha
Amgen Inc. Biotechnics Pfizer
Gilead Sciences Inc. Bharat Biotech Astra Zeneca
Genzyme
Corporation Wockhardt Unilever
Dr. Reddy's
Serono S.A Laboratories Dupont
Serum Institute of
Biogen Idec Inc. India Bayer
MedImmune Inc. Zydus Cadila Eli Lilly
Hoechst Roussel
Chiron Corporation Aventis Pharma Vet
Amylin
Pharmaceuticals Reliance Life
Inc. Sciences Millipore
Invitrogen
Corporation Novozymes

Biotechnology Sector: Introduction

In 2006, India was ranked 3rd in the South-Eastern Asia

region after Korea and Japan on the basis of number of
biotech companies (Ernst and Young). India has about 280
companies in biotech sector. Biocon was ranked India’s
largest biotech company and Rasi was the top Bt cotton
producer in the group.
Sector Outlook

Classification of Sector

SWOT Analysis

Evolution of Biotechnology

With a record growth rate of about 37.42%, Indian biotech

industry has achieved market value of US$ 1.45 billion (Rs.
6521 crore). It has been growing at the pace of 35-40% for
the last three years and is estimated to grow to US$ 5 billion
by 2010.

The immense potential of the sector is clearly visible from its

growth rate. Growing numbers of research laboratories, pool
of qualified scientific talent, widening institutional network,
vibrant clinical potential and fast growing pharma sector are
the important growth stimulants.

India’s ecological and population diversity has played a key

role in the developments in the areas of research and drug
discovery in biotech sector. Government is also supporting
the biotech sector by providing financial and non-financial
incentives at central and state level.

Although Indian biotech industry is just 1.1% of the world

biotech industry, India is soon going to become a prominent
player. Today India is the favorite destination not only for
biotech products, pharmaceuticals and diagnostics but also
for outsourcing of contract research and clinical trials.

According to the BioSpectrum-ABLE survey report in 2006:

¾ BioPharma sector crossed the $1 billion (Rs 4,475

crore) mark, driven by exports worth Rs 2495.24 crore.

¾ BioAgri sector recorded the highest growth.

 ¾ The industry has shown 81 percent growth rate.

¾ The popularity of Bt cotton helped the BioAgri sector to

grow to Rs 598 crore from Rs 330 crore

¾ Serum has shown Rs 703 crore in sales and is ahead of

Biocon Ltd by Rs 15 crore.

Biotech Sector: Economic Outlook

According to Dr Clive James, Founder and President of the

International Service for the Acquisition of Agri- Biotech
Applications (ISAAA), the period 2006-2015 has been
projected as the "decade of Asia" in the field of
biotechnology.

Achieving US$ 1 billion mark with export accounting for US$

756 million is an important milestone for the Indian biotech
sector. Biotech companies are earning huge profits and are
using these profits for further investments, e.g. Wockhardt
acquired Pinewood Laboratories and Reliance Life Sciences
took staked control of GeneMedix Plc.

Some of the important points are:

¾ BioAgri's share of exports reached to Rs 35.88 crore.

¾ BioServices overseas revenues were Rs 684 crore.

¾ Indian pharmaceutical industry is growing at the rate of

over 8 per cent per year.

¾ BioPharma exports amount to Rs 3,357.17 crore (74.33

percent of the total exports).
 ¾ BioInformatics and BioIndustrial sector accounted for
3% and 1.23 % of the total exports respectively.

¾ Ever-increasing investment levels (Rs 1,650 crore

against Rs 1,215 crore previous year).

¾ Investment of 25.3% of revenue in research and

building infrastructure.

¾ Western India is leading with revenues of Rs.3, 234.42

crore (49.6% of Indian biotech share).

Classification of Biotech Sector

Biotechnology is defined as the technology that uses
biological systems, organisms, or derivatives thereof, for the
benefit of humankind. It is a powerful technology with the
potential to transform many industrial sectors like forestry,
fishing, pharmaceuticals and health, agriculture, textiles,
environmental industries and energy and mining, etc. It can
be classified as follows:

• Modern Biotechnology: It is a recent, research based

technology. It performs a range of activities in the areas of
molecular and cellular biology, recombinant DNA technology,
biochemistry, immunology, etc.

• Gene Technology: It is a subset of biotechnology. It

involves scientific manipulation of living organisms at
genetic level to produce new vaccines, hormones, and
monoclonal hormones.

• BioPharma: Therapeutics, diagnostics, vaccines and

animal health care products are its major products.
• BioIndustrial: It consists of organic amino acids,
enzymes, and yeast and yeast-based products.
• BioServices: It involves contract research, contract
manufacturing and clinical research.
• BioAgri: It comprises of biopesticides, genetically
engineered seeds and biofertilisers.
• Bio-IT: Products and services in bioinformatics represent
this sector.

SWOT Analysis of Biotech Sector

STRENGTHS

• Highly skilled and qualified scientific manpower.

• Government taking initiatives to support biotech sector

• Capability in handling fermentation based compounds,

extraction of high quality products using plant and animal
parts.

•Recombinant DNA technology, plant breeding techniques,

plant cell/tissue culture, bioprocess engineering, use of
cell/microbial culture techniques, etc.

•Setting up of effective and efficient biotech enterprises.

• Infrastructure in manufacturing processing equipments and

bio-reactors

WEAKNESSES

• Administration of resources supporting biotech research

and development
• Lack of awareness regarding biotech practices

OPPORTUNITIES

• Accelerated growth of biotech industry

• Increased opportunity of entrepreneurial activity

• Population and ecological diversity

THREATS

• Lack of advanced biotechnologies and products

• Lack of public awareness about biotechnology issues
• Difference between theory and practice in R&D

Evolution of Biotechnology

Biotechnology is a very broad term which is applicable to old

and new, sophisticated and simple, familiar and strange
applications of living organisms– anything from simple
fermentation to sophisticated gene therapy. The evolution of
the biotechnology sector is as follows:

Ancient Biotechnology: Biotechnology is as old as the

ancient culture of Indians, Chinese, Greeks, Romans,
Egyptians, Sumerians and other communities of the world.
Use of microorganisms for fermentation, domesticating
animals for livestock, alcohol in the form of wine and beer,
herbal remedies and plant balms for treatment of wounds
and ailments are a few examples of ancient biotechnology.

Pre-20th Century: Renaissance accelerated the pace of

scientific discoveries in Europe. Galileo, Copernicus,
Leonardo Da Vinci were some of the renaissance leaders
whose knowledge extended over various branches of art,
science and medicine. Microscope, first cork cell, protozoa,
smallpox vaccine, Darwin’s theory of evolution are some of
the famous discoveries relating to this very field.

20th Century: In early 20th century modern biotechnology

movement started, particularly in immunology and genetics.
Penicillin, computers, discovery of DNA as the genetic basis,
use of bacteria to treat raw sewage (bioremediation project)
are significant developments in this direction. Revolution in
forensics and biomedical science took place with the new lab
methods, such as DNA Sequencing, protein analysis,
Polymerase Chain Reaction (PCR). The millennium ended
with the introduction of first cloned sheep Dolly, debate over
the ethical issues relating to biotechnology, stem cell
research, genetic testing and genetically modified
organisms.

21st Century-Nanotechnology, Biotechnology,

Cognitive and Information Sciences (NBIC): 21st
century started with the development of rough draft of
human genome, or map of human life. NBIC combines the
knowledge of biotechnology generated in the past 30 years
to develop abilities in computing advances (information
technology), in manipulating matters at atomic level
(nanotechnology), and in understanding human brain
(cognitive sciences).

Scope of Biotechnology Sector.

In 1978, Circa was the only Indian biotech company that
used to manufacture fermentations and enzyme products.
Today, Indian biotech sector comprises of more than 280
companies, generating revenues of about US$ 1.5 billion.
Indian biotech industry comprises of clinical research, new
drug discovery, bioinformatics, contract R&D,
biopharmaceuticals, etc.

In India, Bangalore has emerged as the largest biotech hub

with a total annual sales revenue of about Rs. 1400 crore.
There are about 175 companies working in the diverse areas
of bioagri, bioindustrial, bioservices, nutraceutical,
biopharma, bioinformatics, herbal products and biosuppliers.

With the supporting policy framework, biogenerics or

biosimilars, bio manufacturing, stem cells and regenerative
medicine have been identified as areas of strategic
importance. Biotech sector achievements are as follows:

• Biotech Industry has 37.42% growth rate per annum

• Biotech industry has reached US$ 1.5 billion

• Bioservices has reached US$ 160 million

• Bioagri sector has crossed US$ 130 million

• Biopharma has reached US$ 1billion

Biotechnology Sector: Future Scenario

Globally, Indian biotech industry has emerged as the

manufacturer of novel and proprietary biotech products. The
factors behind this success are specialized human resource,
internationally benchmarked infrastructure and national
biotechnology strategy.

With 208 biotech companies and 180 bio-suppliers, Indian

biotech industry is worth US$ 1.45 billion. Bio-partnering
and co-developing technologies with American and Chinese
companies will increase the scope of R&D in India.

Emerging investment opportunities and increasing global

visibility has forced Indian biotech companies to develop
business models, improve product commercialization and
make strong market position.
Infrastructure for R&D in protein engineering, molecular
studies, immunological studies and drug designing is also
developing. There is lot of scope in biogenerics sector as
many biological drugs are going off-patent in coming years.

Regulatory framework in association with strong

biomanufacturing skills will help in getting approval for
generic versions of biologicals e.g. GCSF, insulin, Hep B
vaccine, etc.

Jobs in Biotech Sector

According to Dr Manju Sharma, former Director of

Department of Biotechnology, Ministry of Science and
Technology, New Delhi, biotech sector will become the
largest sector for employment of skilled human resource in
near future.

There are huge career opportunities in new biology and new

biosciences. Development of new scientific institutions and
centers for excellence will help young students and scientists
pursue careers in research and development. It will also help
in entrepreneurial development in this sector.

Biotech sector provides professional opportunities in the

following areas:
• Inventorisation, characterization and documentation
• Plant and agriculture related activities
• Testing of GMOs (Genetically Modified Organisms) and
transgenics
• Health care diagnostic
• Industrial biotechnology
• Environmental protection and Biodiversity conservation
• Food processing
• Production of biologicals and other biotech products
• Teaching and training in biotechnology
Career Institutes for Biotech Career Development

Biotechnology Sector: Employment

Top Biotech Institutes in India

• Amity University, Noida, U.P.

• Arunai Engineering College, Tiruvannamalai, Tamilnadu
• Bioinformatics Centre, University of Pune, Maharashtra
• Birla Institute of Technology, Mesra, Ranchi
• BMS Institute of Technology, Bangalore
• Centre for Biotechnology, Jawaharlal Nehru University, New
Delhi
• Department of Biochemical Engineering and Biotechnology,
IIT Delhi
• Department of Biotechnology, Cochin University of Science
& Technology, Cochin
• Department of Microbiology & Biotechnology Centre, The
Maharaja Sayaji Rao University of Baroda, Baroda
• Department of Plant Molecular Biology and Biotechnology,
TN Agricultural University, Coimbatore
• Garden City College, Bangalore
• GM Institute of Technology, Devengare, Karnataka
• Institute of Chemical Technology, University of Mumbai,
Maharashtra
• Jaypee Institute of Information Technology, Noida, U.P.
• National Dairy Research Institute (NDRI), Karnal, Haryana
• Presidency College, Bangalore
• Rajiv Gandhi Centre for Biotechnology, Trivandrum, Kerala
• School of Life Sciences, Hyderabad
• Seeding Academy of Design, Technology and Management,
Silas, Jaipur
• Shree Manibhai Virani & Smt Navalben Virani Science
College, Rajkot, Gujarat
• The Oxford College of Science, Bangalore
• University Institute of Engineering & Technology, Punjab
University, Chandigarh
• University School of Biotechnology, Guru Gobind Singh IP
University, Delhi

Biotechnology Sector: Employment

Biotech Jobs

Biotechnology is a relatively new field. It is a very exciting

sector with tremendous possibilities. It is an emerging field,
yielding wonder drugs and new and improved varieties of
plants and animals. By patenting their research, scientists
get name as well as large fortunes as fruits of their
research.

Research Scientists not only perform experiments in labs but

also devote much of their time in attending seminars,
conferences, teaching university students, writing papers.
Research scientist has a very creative role as he has to work
on the forefront of scientific discovery. He has to decide
what to study, how to study, and thereby he can learn new
things.

Laboratory Assistants and Lab Technicians work on a variety

of sophisticated equipments, prepare chemicals, maintain
experimental microbial, plant, or tissue culture in research
labs. Lab technician helps research scientists in their
scientific discoveries. Lab technician after doing MBA can get
management position in a biotech firm.

Sales Representatives try to sell the biotech industry

products to doctors, farmers, other industries, or sell and
supply scientific equipments to biotech researchers. Quality
Assurance Technicians test the biotech products in labs or
production facilities to ensure that they are safe and meet
the required standards.

BioInformatics Personnel work on designing and maintaining

scientific data and analysing the results of various research
trials.

Job Prospects of Biotechnology in India:

As the biotech industry is growing and commercializing, the

number of job vacancies is also increasing. Companies are
staffing more and more sales force to push their products in
the market. They are also employing trained people for
clinical research so as to get through the clinical approval
process.

This has increased demand for clinical trial managers,

clinical research professionals, clinical research associates
and outsourcing managers. Because of commercialization of
the industry, the demand for finance and administration
personnel is also increasing. Thus, biotech companies are
recruiting people at all levels.

A biotechnologist may also work in government institutes

and organizations. These days agriculture, dairy, horticulture
and drug companies are also employing large number of
biotechnologists. Biotech companies like Dr. Reddy’s Labs,
Ranbaxy, Dabur, and Hindustan Lever have openings in their
R&D facilities.

The starting salary while doing fellowship in a research

institute comes around Rs. 3,000 per month. Private
companies pay around Rs. 5,000-10,000 per month to a
qualified biotechnologist. Currently there is shortage of
trained people in biotech field in India. To overcome the
shortage, Department of Biotechnology is promoting this
field in schools and colleges. Those who wish to work in this
industry can go for a short-term training for
biotechnologists, organized by Biotech Consortium India Ltd.
According to an estimate, 300 biotech companies in India
could provide employment to more than 20,000 students.

At present India has a capacity of less than 700 post

graduate students spread over the various segments like
agriculture, vaccine research, neurosciences, brain cell
research, etc. Although the biotech industry hopes to touch
US$ 25 billion mark by 2015, manpower shortage has
emerged as a major problem that might derail its progress.

Biotech industry survey done by BioSpectrum shows that

despite the fact that over 200 biotech colleges are producing
about 8000 fresh biotech graduates and post-graduates
every year, the industry will face looming shortage of
trained manpower. It points out the huge difference between
the industry’s expectations and availability of quality
manpower. The situation is aggravated by the fact that
students from the top institutions prefer to go abroad for
higher studies rather than taking jobs in India.

Top Players in Biotechnology

Novozymes
Panacea Biotec
Rasi Seeds Pvt. Ltd.
Rossari Biotech
Monsanto India Limited
Shantha Biotechnics Limited
Nuziveedu Seeds Limited
Advanced Enzymes Technologies Limited
Bharat Serums and Vaccines Limited
Maharashtra Hybrid Seed Company (Mahyco)

Other Biotech Companies

Avestha Gengraine

Eli Lilly and Company (India) Pvt. Ltd.

Haffkine Bio-Pharmaceuticals
Indian Immunologicals ltd.

Krebs Biochemicals

Metahelix Life Sciences

Wipro Biomed

Recent Developments
1.Biocon granted marketing license of its cancer drug
to Ferozsons labs

Biocon granted exclusive marketing license of Biomab EGFR,

biotech molecule for the treatment of cancer, to Ferozsons
Laboratories Ltd of Pakistan. The Pakistan oncology market
is valued at nearly $70 million. Biomab EGFR has entered
the rapidly growing monoclonal sector that has annual
growth rate of about 30%. Biomab EGFR is used in the
treatment of neck and head cancer.

2.Favourable decision on Ranbaxy’s case

Federal court of Canada read out a favourable decision on

Ranbaxy’s case against Pfizer. Pfizer marketed Atorvastatin,
cholesterol-lowering drug, as Lipitor. The Court invalidated
Pfizer’s atorvastatin patent CA 2,021,546 as the data
provided didn’t back up the suggestion of ten-fold increase
in activity. On marketing approval, this decision will allow
Ranbaxy’s generic atorvastatin to enter the Canadian
market.
3.Ranbaxy launches asthma inhalation capsules

On 29th March Ranbaxy launched Osovair, asthma

inhalation capsule, which is a combination of long acting ß2
agonist Formoterol and the new inhaled corticosteroid
Ciclesonide drugs.

Osovair is available in Rheocaps as Osovair 160 mcg and

Osovair 320 mcg and can only be used with Ranbaxy's
Rheohaler, a capsule-based multidose dry-powder inhaler.

4.BT cotton to gain India’s cotton area

According to Kishorilal Jhunjhunwala, president of the East

India Cotton Association, the genetically modified cotton had
covered 9.1 million hectares of total area for cotton
production in 2006-07 with good yield and prices.

The genetically modified cotton covered 35% of the total

area with cotton yield rising to 500 Kg per hectare. Farmers
are aggressively buying Monsanto Company’s BT
cottonseeds, which help fight bollworms, a major worry for
Indian farmers.

It is estimated that the domestic cotton production will go

up to 27 million bales and the total cotton export would
cross 4 million bales by September 2007. But the
environmental groups have opposed BT seeds claiming that
they deplete bio-diversity.

5.Supreme court’s approval for conducting field trials

The Supreme Court has given approval for conducting field

trials of genetically modified seeds but with certain
restrictions. The genetically modified (GM) crops are
expected to increase productivity, reduce crop losses due to
worm attacks and lower pesticide use. This permission will
help in large-scale field trials of BT brinjal of Maharashtra
Hybrid Seeds Company (Mahyco).

India is doing field trials of GM seeds of mustard, corn,

cauliflower, brinjal, rice, etc and expecting to repeat the
results of GM cottonseeds. The restriction came in the form
of increase in the isolation distance between the GM crop
fields and other fields. Earlier there was no such isolation
restriction. The court said that a designated scientist would
make sure that all the conditions are complied with during
the trial.

6.Biocon granted marketing license of its cancer drug

to Ferozsons lab

To claim share in the drug distribution market, the Reliance

Anil Dhirubhai Ambani Group (ADAG) is planning to have a
tie up with a multinational distribution company MNC to float
its pharma retail chain business.

7.Insulin created from child’s stem cells

From the stem cells taken from child’s umbilical chord,

scientists from the University of Texas Medical Branch at
Galveston have successfully created insulin in lab. It is a
medical breakthrough, a promise to cure Type 1 diabetes,
which is a chronic lifelong disease that occurs when the
pancreas does not produce enough insulin to properly
control blood sugar levels.

8.First adult liver transplant in Bangalore

On 20th April, first successful living donor liver transplant

was carried out at Narayana Hrudayalaya in Bangalore. It
was a 17-hour split liver transplant surgery wherein a large
chunk of the liver of the spouse (65% of the right lobe of
liver) was transplanted into the husband suffering from
cirrhosis of liver.

9.India lags behind in Biotech, says Ernst report

According to the new study report by Ernst & Young, Indian

Biotech industry is growing but it badly needs funds,
especially during early stages of new drug development
process, for the sustainable industry development. It should
start filing more original patents in novel drugs too.

The report also points to the possibility of India following the

Japanese path and moving up the value chain of new drug
development.

10.ASSOCHAM: Biotech sector to touch US$ 5 bn by

2009-10

According to ASSOCHAM, with a consecutive CAGR of

35.1%, the Biotech sector is expected to grow to US$ 5
billion by 2009-10. Accounting for 52% of the industry’s
total revenue, Biotech sector exports are valued at US$ 763
million. With a growth rate of 36%, the investments in the
sector have grown to US$ 360 million in 2005-06. Currently,
there are more than 300 biotech companies focusing on
different aspects of value chain and this figure is expected to
double in the next 3-4 years.

With a growth rate of 32%, Biopharma sector has grown to

US$ 1 billion in 2005-06. It accounts for over 70% of
domestic sales and 75% of total exports. Agri Biotech and
BioServices are registering fastest growth and Vaccines and
Bio-Generics are the common areas of interest for the
leading biotech companies.

In coming 3-4 years, apart from the knowledge-based

industry, a series of joint ventures will come up in
application of biotechnology in horticulture, agriculture and
viticulture. The sector has the potential to attract funding
from international bodies like World Bank, International
Finance Corporations, Ventures Capitals and Private Equity
Arms.

11.Eli launches diabetes awareness camp

On 28th May, Under ‘Peaks and Valley’s Complications

Check’ (PVCC) programme, Eli Lilly announced that it has
the target of providing free treatment to about 50,000 high-
risk diabetes patients across the country in the next three
years. This programme was launched on the occasion of
‘Insulin-discovery Week’.

The company would shortlist patients through free medical

checkups in 20,000 camps in 50 Indian cities, including the
four metros. The camp would function in collaboration with
private physicians and hospitals. At the PVCC programme,
physicians would provide additional care in the form of
comprehensive check-up packages that will include a test for
eye and kidney problems and foot examination along with
the usual blood glucose test.

12.Bangalore Bio 2007 starting from 7th June 2007

Bangalore International Exhibition Centre (BEIC) announced

that in Bangalore Bio 2007, a three-day biotech event
starting from 7th June 2007, 11 Indian states would present
themselves as the ideal destination for setting up facilities
for R&D in the biotech sector. The confirmed states are
Andhra Pradesh, Chhattisgarh, Gujarat, Haryana, Himachal
Pradesh, Jharkhand, Kerala, Maharashtra, Orissa, Rajasthan
and Uttar Pradesh. Key decision makers from these states
will have the opportunity to absorb a superior content to
make strategic decisions for the development of biotech
industry in their respective states. This event is promoted by
the Government of Karnataka and organized by Vision Group
of Biotechnology

13.Two Indian projects shortlisted for Green Oscars

Two Indian biotech projects, BIOTECH from Kerala and SKG

Sangha from Karnataka, have been short-listed for the
Ashden Awards for Sustainable Energy, popularly known as
the “Green Oscars”. These projects will have to compete
with the contestants from China, Ghana, Nepal, Peru,
Bangladesh, Philippines, and Tanzania for five awards. The
award and the prize money of more than 200,000 pounds
(Rs. 17 lakhs approx) will be presented by Former US Vice
president Al Gore at the Royal Geographical Society on June
21.

14.Zenotech setting up plasma fractional facility

Zenotech Laboratories, Hyderabad based generic

biopharmaceutical company, is planning to set up a plasma
fractional facility at an investment of US$ 20-25 million. The
facility will be engaged in disaggregating the various
proteins in plasma.

The global market size for plasma ingredients is estimated at

US$ 20 billion, of which the main proteins including
immunoglobulins have a market size of US$ 2 billion.
Sources said that the possible locations for the facility are
Vizag and Vijayawada. The company already has three
facilities in Hyderabad. The proposed facility would be in
compliance with the US/EU regulatory standards.
15.Lupin and Wockhardt got USFDA approval

Lupin and Wockhardt got USFDA nod for Cefadroxil and anti-
fungal drug. India’s Lupin Ltd. got US FDA approval for its
generic antibiotic Cefadroxil capsules whereas drug maker
Wockhardt received USFDA approval to enter the market for
Lamisil, an anti-fungal drug.

16.US drug co plans to recall contact lens care

solution

Advanced Medical Optics Inc (AMO), US-based ophthalmic

drug major, has decided to withdraw its contact lens care
solution AMO Complete Moisture Plus from the Indian
market on grounds of its adverse reaction in US market.

According to the US Centers for Disease Control &

Prevention (CDC), the drug triggers a rare but serious eye
infection, Acanthamoeba Keratitis (AK). AK may lead to
vision loss with some patients requiring a corneal transplant.
The consumers who used Complete Moisture Plus solution
have seven times greater risk of developing AK.

The USFDA has advised consumers to replace their lenses

and storage containers who have used AMO’s solution. The
symptoms of Acanthamoeba Keratitis can be similar to those
of other more common eye infections and may include eye
pain or redness, blurred vision, light sensitivity, sensation of
something in the eye or excessive tearing, but
Acanthamoeba is more difficult to treat.

17.Glenmark eyes pain management market

Glenmark’s Swiss subsidiary has completed phase I clinical
trials for a pain reliever, GRC 6211, and is planning to
launch the molecule in 2011. GRC 6211 is an antagonist
compound for a range of pain indications like osteoarthritis,
urinary incontinence and naturopathic pain.

Glenmark is in discussions with the potential partners for

licensing this compound. Pain management has a large
unmet market and companies are trying to capture this
large market. Merck, GSK and Pfizer also have molecules
under development in the same category.

18.Aurobindo gets US FDA nod for Cefprozil tablet

Aurobindo Pharma, Indian drug maker, received USFDA nod

for its Cefprozil tablet – a second generation cephalosporin
antibiotic in strengths of 250 and 500 mg. This approval will
help Aurobindo to enter the US$ 80 million market of
antibiotic Cefzil in the US.
 TOP PLAYERS

1. Novozymes

Novozymes is a leading biotech-based company in enzyme

and microorganism segment. It is present in over 40
different industries and 130 countries and is marking its
presence in India through Novozymes South Asia Pvt. Ltd.
Its product portfolio includes over 100 types of enzymes and
microorganisms and about 700 different products.
Novozymes has state-of-art expertise in biotechnology,
microbiology and gene technology and spends about 11-
13% of sales on R&D. It has biotechnology as the core
competence, as it helps Novozymes to discover, develop and
produce enzymes and microorganisms as per the customer
needs. Core competencies of Novozymes are as follows:

• Genetic & biochemical diversity

• Strain development & improvement
• Protein chemistry
• Pathway engineering
• Large-scale production
• Protein design

Novozymes has employee strength of about 4000 in 30

countries. There are about 47% in Production & Quality,
33% employees in Sales & Marketing and Administration,
and the remaining 20% are in Research & Development.

Board of Directors

• Steen Riisgaard, President & CEO

• Anna Lise Mortensen Grandjean, Vice President-Stakeholder
Communication & Sustainability Development
• Nickie Inger Spile, Vice President-People & Organisation
• Benny D. Loft, Executive Vice President & CEO-Finance, IT
and Legal
• Per Falholt, Executive Vice President & CSO-Research &
Development
• Peder Holk Nielson, Executive Vice President-Sales &
Marketing
• Arne W. Schmidt, Executive Vice president-Development,
Production & Quality

Contact Address:
Novozymes
Krogshoejvej 36
DK-2880 Bagsvaerd
Phone: +45 88 24 99 99
Website: www.novozymes.com
 2. Panacea Biotec

Panacea Biotec is a leading biotech company with focus on

the research, manufacturing and marketing of
biopharmaceuticals, natural products and vaccines and new
chemical entities.

Panacea has achieved a growth of about 48.9% with a

turnover of Rs. 6112.2 million during the year ending on
31st December 2006. It has been ranked 3rd among biotech
companies and 6th among the pharmaceutical companies in
India.

Panacea has launched almost 43 brands in various

therapeutics segments like immuno-suppressants, anti-
osteoporosis, pain management and anti¬¬- diabetics. It
has marked its presence in the markets of Africa, CIS,
Middle East Asia, Uzbekistan, China, Myanmar, Thailand, and
Bangladesh, Cambodia, and Malaysia.

It has entered into an in-licensing arrangement with National

Institute of Health, USA for peptide-based products, and
strategic collaboration with UK based Cambridge Biostability
Ltd. for development of new vaccine delivery system.

With intellectual property of about 200 scientists, the

company has two state-of-art R&D facilities in Delhi and
Punjab. It spends almost 6% of its net sales on R&D. Its
Pharmaceutical and Vaccine formulation plant in New Delhi
has WHO-cGMP certification. Now it is planning to increase
the number of scientists to 500 and R&D facilities to 5.

The R&D at panacea is focused on:

• New Drug Discovery Research (NDDR)

• Formulations Research (Drug Delivery Technologies)
• The Advanced Drug Delivery Research Centre
• Bio-pharmaceutical Research (Newer Vaccines, Peptides &
Monoclonal Antibodies)
• Newer & Combination Vaccines Products:

1. Nimulid Tablets
2. Nimulid Safeinject
3. Panimun
4. Alphadol
5. Enivac HB
6. Manyana Tablets
7. Bukatel
8. ZINC-Naproxen
9. 0394
10. Rifampicin
11. Lovastatin + Niacin-ER
12. Atorvastatin and Ezetimibe
13. Mirtazapine
14. Tacrolimus
15. Ciprofloxacin + Ornidazole
16. Glizid MR
17. Betaglim

Board of Directors

A. Whole-Time Directors (Promoters)

1. Mr. Soshil Kumar Jain, Chairman
2. Mr. Ravinder Jain, Managing Director
3. Mr. Rajesh Jain, Joint Managing Director
4. Mr. Sandeep Jain, Joint Managing Director
5. Mr. Sumit Jain, Director - Operations & Projects

B. Non-Executive Directors (Under Corporate Governance)

1. Mr. Sunil Kapoor, Director

2. Mr. R.L. Narasimhan, Director
3. Mr. N.N. Khamitkar, Director
4. Mr. M.L. Kalra, Director
5. Mr. Gurmeet Singh, Director
6. Mr. K.M. Lal, Director
7. Dr. A.N. Saksena, Director

Contact Address: Head Office

B-1 Extn. / A-27,
Mohan Co-operative Industrial Estate,
Mathura Road, New Delhi- 110044, India.
Phone: +91-11- 41678000, 26945270, 26974500
Fax : +91-11-41679081
Email: corporate@pblintranet.com
Website: www.panacea-biotec.com
 3. Rasi Seeds (P) Ltd

Rasi Seeds was founded by Mr. M.Ramasami in 1973 in Attur

located in Salem district of Madras. Initially it was into
research and development in cotton seeds, and now it is into
multi-crop, multi-location quality research movement for the
benefits of farmers.

The R&D facility of Rasi has got recognition from

Department of Scientific and Industrial Research, Ministry of
Science and Technology, Government of India. It is a 140
acres research farm with 55,000 sq.ft. for Green House. It
has state-of-art biotech facility, fiber testing lab (HVI) and
seed testing lab.

Rasi has the proprietary cotton hybrid viz. RCH 2 Bt. It has
developed about 1150 cotton hybrids of different
characteristics. In 1999, Rasi and Monsanto tied-up for the
commercialization of hybrid cotton with Bollgard technology.
Rasi has about 10,000 farmers for direct seed production. It
arranges pre-season technical meeting with the seed grower
farmers so as to get the best quality and more productivity.

Its product list includes:

• Cotton
• Sunflower
• Vegetables
• Maize
• Pearl Millet
• Paddy

Contact Address:

Rasi Seeds (P) Ltd

273, Kamarajanar Road
P.O. Box No: 30,
Attur – 636 102
Salem District,
Tamilnadu, India.
Phone: +91-4282-241007, 242007
Fax: +91-4282-242558
E-mail: rasimail@rasiseeds.com
Website: www.rasiseeds.com
 4. Rossari Biotech India Pvt. Ltd

Rossari Biotech India Pvt. Ltd is the largest manufacturer of

enzymes and among the leading specialty chemical
manufacturers for textile processing. It was established in
1997 and has recently got ISO 9001: 2000 certifications.

Rossari is in the business of designing, manufacturing and

marketing of enzymes and textile auxiliaries. It exports its
products to Sri Lanka, Bangladesh, UAE, Australia, Malaysia,
Kenya, New Zealand, Jordan, China, Venezuela, and Nepal.

Rossari has its corporate office in Mumbai and factory at

Nhavasheva port, near Mumbai. Its R&D centre is in New
Mumbai. Its product range includes Fragma, Flameshield,
Hydrogard, Fabshield and Snocool

as well as high concentrates and standard formulations of

Acid cellulose, Neutral Cellulose, High Temperature Stable
Amylases and Catalyses, Engineered Acid Cellulose (for low
colour loss) Amylases.

Its product range is as follows:

• ANTIFUNG SP Conc
• D soft New
• Dymax NDA
• Newfade PUN Pdr
• Temper VLF New liquid
• Temper VLF New
• Zycol SNE SU
• Zywet P 100
Contact Address:
Rossari Biotech India Pvt. Ltd
401, Omega, Main Street,
Hiranandani Gardens,
Powai, Mumbai - 400 076.
Phone: 91- 22- 2570 9200 / 2570 9201
Fax : 91- 22- 25709210
Email: enquiry@rossarimail.com
Website: www.rossari.com
 5. Monsanto India Limited

Monsanto began its work in India about 50 years back, soon

after independence. It is into the business of agricultural
inputs. Machete, first rice herbicide, was launched by the
company in 1975. The company is functioning dedicatedly to
develop high-yield crop varieties and hybrid crops. Over the
years it has provided enduring solutions to the farmers.

Monsanto India is an informal, flat, and team based

organization that empowers employees and provides
opportunities for personal as well as professional growth. It
is working with the steady drive to be the leader in
innovation, technology and market share.

Using innovative technology, Monsanto provides integrated

solutions to the farmers worldwide, thereby helping them to
produce quality food and fibre. It has a research centre in
Bangalore with state-of-art facilities. It covers an area of
about 50,000 sq.ft. and has about 50 scientists, assisted by
software programmers, administrators and consultants.

Executive Officers

• Hugh Grant, Chairman, President and Chief Executive

Officer
• Brett D. Begemann, Executive Vice President,
International Commercial
• Carl M. Casale, Executive Vice President, North America
Commercial
• Richard B. Clark, Vice President and Controller
• Terrell K. Crews, Executive Vice President and Chief
Financial Officer
• Scarlett Lee Foster, Vice President, Investor Relations
• Dr. Robert T. Fraley, Executive Vice President and Chief
Technology Officer
• Janet M. Holloway, Vice President and Chief of Staff
• Mark J. Leidy, Executive Vice President, Manufacturing
• Steven C. Mizell, Senior Vice President, Human Resources
• Cheryl Morley, Senior Vice President, Corporate Strategy
• Robert A. Paley, Vice President and Treasurer
• Nicole Ringenberg, Vice President, Finance
• David F. Snively, Senior Vice President, Secretary and
General Counsel
• Gerald A. Steiner, Executive Vice President, Commercial
Acceptance

Products

I. Farm Inputs:
• Round up: Broad Spectrum Herbicide
• Machete: Transplanted Rice Herbicide
• Fastmix: Transplanted Rice Herbicide

II. Seeds:

A. Maize: Maize hybrids are available under the umbrella

brand name DEKALB.

DEKALB Maize Hybrids

• SUPER 900M
• HI-SHELL
• ALLROUNDER

B. Sunflower: Sunflower is available under the umbrella

brand name ASGROW.

ASGROW Sunflower Hybrids

• SH 3322
• SH 41
• SH 177

C. RICE: Rice is sold under the umbrella brand name

FRONTLINE.
FRONTLINE Hybrid Paddy Seeds
• RH 257
• RH 664

Contact Address:

Monsanto India Limited

Ahura Centre, 5th Floor
96, Mahakali Caves Road
Andheri (East), Mumbai 400 093
India
Phone: 91 22 28246450 / 67029851
Fax: 91 22 28244707 / 67023361
Email: biotechinfo@monsanto.com
Website: www.monsantoindia.com
6. Shantha Biotechnics Limited
Shantha Biotechnics Limited

In 1993, Shantha Biotechnics limited was founded by Dr. K I

Varaprasad and Dr. Varaprasad with the aim of
manufacturing efficient and cost effective therapeutics and
vaccines. It develops and manufactures health care products
using biotechnology techniques. Its products are supplied to
markets of Africa, Asia-Pacific, CIS and Latin America as well
as to UNICEF and PAHO.

The company’s R&D center at Shantha is equipped with the

latest instruments and other facilities. It focuses on the
development of proteins and vaccines, generic biologicals
and novel therapeutic antibodies. It undertakes contract
research in the areas of:

• Monoclonal antibody development

• Gene cloning
• Analytical method
• Expression and purification of recombinant proteins by
fermentation
• Development of WCB and MCB
• Fermentation/Purification Process optimization
• Development of polyclonal antibodies

WHO has pre-qualified SHANVAC-B, Hepatitis-B vaccine

being manufactured by Shantha. In November 2006
Shantha Biotechnics Limited became part of France based
Merieux Alliance group. The group has employee strength of
9,000 people worldwide and turnover of about US$ 1.3
billion.

Board of Directors
• Mr. Georges Hibon, Chairman
• Dr. K.I. Varaprasad Reddy, Managing Director
• Mr. Khalil Ahmed, Executive Director
• Mr. Alain Merieux, Director
• Mr. Philippe Sans, Director
• Mr. Johannes Burlin, Director
• Mr. Abhey Yograj, Director
• Mrs. Harsha Bangari, Director (Exim Bank Nominee)

Products
• Shanvac-B (r-DNA Hepatitis B Vaccine)
• Shanferon (recombinant interferon Alfa 2b)
• Shankinase (recombinant streptokinase)
• Shanpoietin (recombinant human erythropoietin)
• Shantetra (DPT +H vaccine)
• CYTOCREST (Range of therapies in cancer care)
• Elisa Kits

Contact Address:

SHANTHA BIOTECHNICS INDIA

3rd Floor, Serene Chambers,
Road No.7, Banjara Hills,
Hyderabad - 500 034
INDIA.
Phone: +91-40-23543010, 23548507, 23608843
Fax: +91-40-23548476
E-mail: info@shanthabiotech.com
Website: www.shanthabiotech.com
 7. Nuziveedu Seeds Limited (NSL)

Nuziveedu Seeds Limited has emerged as a leading Agri-

Biotech company. It has about 35% of the market share in
the hybrid cotton seed market in India. It has developed its
core capabilities in research, production, quality assurance
and marketing.

Nuziveedu is mainly into the business of seeds, but has also

entered other fields of power, sugar, spinning/textile, etc. It
has a customer base of about 65 lakh farmers, marketing
network of 1395 distributors & dealers and over 20000 sub-
dealers in 12 states of the country.

Nuziveedu Seeds Limited was founded in 1973 with the aim

of manufacturing good quality seeds. Mr. M. Venkataramaiah
is the Founder and Chairman of Nuziveedu Seeds and Mr.
Prabhakar Rao joined the company as Managing Director in
1982.

Nuziveedu has R&D center at Kompally, and research farms

at Hyderabad, Nizamabad, Gurazala, Guntur and Gurgaon. It
has GOT farms for genetic purity testing at Guntur,
Nuziveedu, Medak, Nizamabad and Hyderabad.

Products

COTTON
• NCS-145 (Bunny & Bunny Bt)
• NCS 207 (Mallika & Mallika Bt)

SORGHUM
• NSH 27 (Sona)
• NSH 36(Bhagyasree)

MAIZE
• NMH-589 (Suvarna)
• NMH 145 (Ajay)
• NMH-234 (Kamadhenu)

SUNFLOWER
• NSFH 36 (Sreshta)
• NSFH - 9 (Mangala)

PEARL MILLET
• NBH-1035(Shanti)
• NBH-2123(Revathi)
• NBH-252 (Pandhari)

Vegetables TOMATO
• Tomato hybrid Surya
• Tomato hybrid NTS 608

BRINJAL
• NBH 696
• NBH 750 (Mahanandi)

CHILLIES
• NCH 1233 (Siri)
• NCH 1236(Sampada)

PADDY
• NP-360(Moti)
• NP-950 (Sourabh)
• NP-45 (Harsha)

Contact Address:
Corporate Office: SECUNDERABAD:
Nuziveedu Seeds Limited
7c, Surya Towers,
105, S.P.Road,
Secunderabad-500 003.
Ph: 91-40-27898008, 55334300 Fax: 55321500
E-mail: info@nuziveeduseeds.co.in
Website: www.nuziveeduseeds.co.in
 8. Advanced Enzymes Technologies Limited

Advanced Enzymes Technologies Limited was founded by Mr.

L.C. Rathi in 1989 with the aim of providing eco-friendly
solutions to all industrial problems as well as for the
healthcare related problems. This research-based company
has achieved market leadership in manufacturing of
probiotics and enzymes.

With its far-reaching experience in biotechnology, Advanced

Enzymes has established its presence across 30 countries
and 25 industries. Advanced Enzymes has its head office in
Mumbai and a team of 180 people worldwide. Its R&D team,
comprising of biochemists, microbiologists, food
technologists and chemical engineers, is focused on New
Application Development. It has achieved specialization in
providing individual specific enzyme solutions.
The R&D team of Advanced Enzymes is headed by Mr. Vic
Rathi (Chairman) and Mr. C.L. Rathi (Managing Director)
who are experts in the Enzyme Industry. Its rapidly
expanding range of products includes different types of
carbohydrases, cellulases, proteases, lipases and amylases.

Products & Solutions

• Agriculture
• Animal Nutrition Healthcare
• Bakery Industry
• Brewery Distillery
• Environment Management
• Fruit Juice Processing
• Leather
• Pharmaceuticals
• Starch Processing
• Tea Processing
• Textile Processing
Contact Address:
Advanced Enzymes Technologies Ltd.
'A' Wing, Sun Magnetica,
5th Floor, Accolade Galaxy,
LIC Service Road,
Louisewadi, Thane 400 604.
Telephone: +91-22-2583 8350 –54, +91-22-25830188.
Fax: +91-22-25835159.
Website: www.enzymeindia.com
 9. Bharat Serums and Vaccines Limited (BSV)

Bharat Serums and Vaccines Limited (BSV), established in

1971, aimed to develop specialized health care products for
the quality conscious market. It manufactures and market
biologicals, biotechnology products and pharmaceuticals.

With a CAGR of about 50% for the last three years, Bharat
Serums and Vaccines Ltd. is one of the fastest growing
pharmaceutical companies in India. Currently, it holds a
major market share of plasma derivatives and by
introducing new and improved therapies it is increasing its
range of products. It has a product portfolio of about 25
brands.

Bharat Serums has two manufacturing sites at Thane and

Ambernath. Its R&D is focused on developing superior drug
delivery systems, creating IPR, improving existing products,
and using emerging biotech tools for monoclonal antibodies
and recombinant products. It is spending almost 7% of its
turnover on R&D.

BSV offers a wide variety of career opportunities and benefit

packages. It treats employees as valued asset. It has talent
from diverse backgrounds so as to have expertise,
imagination and dedication for prosperous tomorrow.

The Board of Directors of Bharat Serums and Vaccines

comprises of the following:

Dr. Vinod G Daftary, Chairman Emeritus

Mr. Bharat V. Daftary, Chairman and Managing Director
Dr. Gautam V. Daftary, Managing Director
Mr. Nilesh R Ganjwala, Finance Director
Mr. Shahzaad Dalal, Nominee Director, ILFS Investment
Managers Limited
Dr. Dilip Mehta, Professional Director
Mr. Prakash Shah, Professional Director

Products

• Plasma Derivatives
• Monoclonals
• Equine Antitoxins and Serums
• Cardiovascular
• Antifungals
• Anaesthetics
• Hormones

Contact Address:
Bharat Serums and Vaccines Limited
Hoechst House, 16th Floor,
Nariman Point,
Mumbai – 400021.
Maharashtra, India.
Tel. No.: 91-22-56560900
Fax. No.: 91-22-56560901
E-mail: corporate@bharatserums.com
Website: www.bharatserums.com
 10. Maharashtra Hybrid Seed Company (Mahyco)

Maharashtra Hybrid Seed Company (Mahyco) was founded

by Dr. Badrinarayan R. Barwale in 1964. Mahyco has
endeavored to produce high quality hybrid seeds and is
engaged in research area of plant generics. It is the first
private enterprise in India to manufacture and market
hybrids of sunflower, pearl millets, cotton, sorghum and
wheat.

With the use of gene transfer technology, it is trying to

develop genetically enhanced crops. In 2002, it became the
first Indian company to commercially grow and market
transgenic crop - Bollgard cotton. Today, it is into research,
production, processing and marketing of about 115 products
in 30 crop species, including oilseeds, fibre, vegetables and
cereals.

Mahyco has research facility at Dawalwadi near Jalna

(Maharashtra). It has the largest multi-locational ISO
certificate (covering 59 locations). There are about 100,000
farmers working in its production centres. It has a network
of 30 production centres and over 5000 sales outlets.

In 1999, quality assurance laboratory of Mahyco became a

member laboratory of International Seed Testing Association
(ISTA), Zurich, Switzerland and in April 2007, it got the
status of ISTA accredited laboratory. This lab offers facility
of seed testing and issues blue, green and orange ISTA
International Seed Analysis Certificate for Germination,
Physical purity, Moisture and Determination of other seeds
(OSD).

At Mahyco plant biotechnology is an integral part of plant

breeding programs. Traits of value are the focus of biotech
research. Major research areas include:
• Crop Transformation
• Molecular Virology
• Molecular Microbiology
• Gene Discovery and Molecular Markers
• Entomology

Contact Address:
Maharashtra Hybrid Seed Company,
Dawalwadi, PO Box 76,
Jalna, India 431203
E-mail: info@mahyco.com
Phones (Research): +91-2482-262371-75, 262001
Phones (Marketing): +91-2482-233881, 233882
Fax: +91-2482-262002
Website: www.mahyco.com
 11. Avestha Gengraine

Avestha Gengraine Technologies Pvt. Ltd. is a fully

integrated biotechnology and bioinformatics company
focusing on the development of preventive personalized
medicines by achieving convergence between food,
pharmaceuticals and clinical genomics. In 2006 the company
had achieved turnover of Rs.18 crore and operating profit of
Rs.1.8 crore and is expecting a turnover of about Rs.35-40
crore in 2007.

Avesthagen was founded in 1998 by Dr. Villoo Morawala-

Patell. It has 4 main strategic business units, viz.
Biopharmaceuticals units, Biotherapeutics units, Food for
medicine (FFM) unit, and Agri-biotech unit. Today it has a
dedicated team of about 250 employees of which more than
25 are PhDs. It has 55 patents in the agri-biotech business.
In 2003, Avesthagen got US patent for genetically modified
technology for every commercially available hybrid seeds.

Avesthagen has a world class, state-of-the-art laboratory at

the International Tech Park in Bangalore. ICICI Ventures,
Cipla Ltd., Tata industries, Godrej Industries and bioMérieux
(France) have invested in Avesthagen. Its R&D is focused
on:

• Transcriptome (Expression) Analysis

• Bioinformatics
• Metabolome Analysis and Lead Optimization
• Genome Analysis
• Recombinant Protein Expression

In 2007, Avesthagen raised Rs. 150 crore from Groupe

Limagrain, Groupe Danone and other strategic investors.
Currently, Jacob Ballas Capital is planning to take a minority
stake in Avesthagen with an investment of US$ 10 million.
Avesthagen is investing Rs.100 crore in expansion and new
research projects in Hyderabad.

Job
S.
Job Title Qualifications Experience Responsibili
no
ty
Optimizatio
n of
Upstream &
Downstrea
Manager -
7-12 years m process
Biopharma M.Sc/PhD
experience in and scale
ceutical (Molecular
1 reputed up.
Process Biology/Cell
pharma Responsible
Developme Biology)
company for setting
nt
up cGMP
Process
Developme
nt Lab.
Minimum 1-2
Research years of
Associate - experience in
M.Sc. (Molecular
Upstream mammalian
2 Biology/Cell
Process cell culture
Biology)
Developme and
nt mammalian
fermentation
Minimum 8 Develop
years of and
General experience in implement
Manager - M.Sc./PhD in the protocols,
3
Clinical Life Sciences Biologics/Phar lead and
Trials maceutical manage
industry. CRO
Including relations
 monitoring
and managing
clinical trials of
new vaccines
or drugs
Responsible
for
Minimum 5
Biopharmac
years
euticals
experience in
and
Project Clinical
M.Pharm/M.Sc/ Bionutrition
Manager - Pharmacology,
4 MVSc/MBBS al clinical
Clinical Well versed
with MD trials,
Trials with Clinical
Develop
drug
and
development
implement
process
protocols,
GCP.
Minimum 3-4
Project years of
Manager - M.Sc./PhD experience in
Upstream (Molecular mammalian
5
Process Biology/Cell cell culture
Developme Biology) and
nt mammalian
fermentation.

Interested candidates can apply for the above jobs by

registering themselves on the career page at
www.avesthagen.com or by mailing their resumes to
info@avesthagen.com
Board of Directors

1. Mr. Darius E. Udwadia - Chairman

2. Dr. Villoo Morawala Patell - Founder, Vice Chairperson
& Managing Director
3. Dr. Simon G. Best- Director
4. Dr. Marc van Montagu- Director
5. Dr. Barry Furr - Director
6. Mr. Nadir Godrej- Director
7. Mr. Aluri Srinivasa Rao - Director
8. Mr. Koen Wentink- Director
9. Ms. Farah Morawala Patell- Director

Contact Address:

Avestha Gengraine Technologies Pvt. Ltd.

"Discoverer", 9th Floor, Unit 3
International Technology Park
Whitefield Road, Bangalore 560066, India
Tel: +91-80-2841 1665/2308/2770/2766
Fax: +91-80-2841 8780
E-mail: info@avesthagen.com
Website: www.avesthagen.com
 12. Eli Lilly

Eli Lilly was founded by pharmaceutical chemist, Eli Lilly, on

10th May 1876. Its global headquarters are at Indianapolis,
Indiana (USA). In 2006 it had achieved revenues of about
US$ 15.57 billion.

It has worldwide employee strength of over 41,502, of which

over 8,262 are engaged in R&D activities. In 1923, Eli Lilly
commercially manufactured and marketed Iletin, the first
insulin product.

Eli Lilly has manufacturing facilities in over 30 countries,

R&D facilities in 9 countries and conducts clinical research in
more than 50 countries. Its products serve markets of about
143 countries. It spends about US$ 3129 million per year on
R&D.

Eli Lily and Company (India) Pvt. Ltd. is a subsidiary of the

US pharmaceutical company, Eli Lilly and Company. It was
established in 1993 as Eli Lilly Ranbaxy Ltd, a 50:50 joint
venture between Eli Lilly and Ranbaxy Laboratories Ltd. With
the acquisition of 50% stake from Ranbaxy in 2001, Eli Lilly
and Company created its Indian subsidiary as Eli Lilly and
Company (India) Ltd.

In India, Eli Lilly has employee strength of about 550, which

includes more than 20 clinical research professionals. Its
revenues grew to Rs. 150 crore in 2003 from Rs. 8 crore in
1994. On 24th March 2007, it announced donation of US$
50 million to fight TB infections in India. About 14 public and
private organizations will join the company as international
partners in this campaign.
Executive Management

Rajiv Gulati, Chairman and managing Director-Eli Lilly India

Pvt. Ltd.
Sidney Taurel, Chairman and Chief Executive Officer
John Lechleiter, President and Chief Operating Officer
Scott Canute, President, Manufacturing Operations
Bryce Carmine, President, Global Brand Development Teams
Deirdre Connelly, President, Lilly USA
Newton F. Crenshaw, President and General Manager, Lilly
Japan
Patrick James, President, Elanco Animal Health
Peter Johnson, Executive Director, Corporate Strategic
Planning
Lorenzo Tallarigo, President, International Operations
Jacques Tapiero, President, Intercontinental Operations

Products:
Huminsulin
Xigris
Gemcite
Distaclor
ReoPro
Alimta

Contact Address:

Eli Lilly and Company (India) Pvt. Ltd.

Plot # 92, Sector 32,
Institutional Area,
Gurgaon-122001
HARYANA, INDIA
Phone : 91-124-2823000,01
Fax : 91-124-2823012, 13
Email : lillyindia@lilly.com
Website: www.lilly.com
 13. Haffkine Bio-Pharmaceutical

Haffkine Institute was founded by Dr. Waldemar Mordecai

Haffkine on 10th January 1899. It is located in Parel in
Mumbai. In 1975, it was divided into Haffkine
BioPharmaceutical Corporation Ltd and Haffkine Institute of
Training, Research and testing, focused on vaccine
production and research. Recently, it has been short-listed
by the Maharashtra government as the future institution for
providing clinical trial training to doctors, pharmacologists
and scientists across India.

Haffkine BioPharmaceutical Corporation Ltd developed first

indigenous oral polio vaccine (OPV). Owing to strategic
planning and sustained efforts, the company has been
increasing its profits since 1997-98. It had employee
strength of about 600 in 2001-02. Its R&D laboratory in
Pimpri has been producing antitoxins and sera for scorpion
and snake venom, diphtheria and tetanus toxins. It has a
well-equipped animal-breeding lab in Mumbai.

In 1977, Haffkine Ajintha Pharmaceuticals, a subsidiary in

collaboration with Western Maharashtra Development
Corporation Ltd, was established in Jalgaon. It produces
capsules, tablets, powders, etc., which are supplied to
Maharashtra government institutions and hospitals.

Haffkine Bio-Pharma's Products

S.no Job Title

Viral vaccines: Other formulations

Poliomyelitis vaccine (oral) Tablets:
Calcium with vitamin d nfi
Antitoxins & sera: Iron and folic acid ip
Snake antivenin
Antiscorpion venom serum
Bacterial vaccines:
Plague vac. I.p.
Injectables:
Adrenaline tartrate inj. Ip
Morphine injection ip.
Liquid orals:
Paracetamol syrup
Protonic h syrup
Paracetamol ip.
Vit b complex (t) nfi
Poly vitamin nfi
Capsules:
Tetracycline ip.
Antiseptic:
Haffkinol liquid
Haffkinol cream

Contact Address:

Haffkine Bio-Pharmaceutical
Acharya Donde Marg,
Parel, Mumbai, India
Tel. No.: 091- 22 4129320-22, 4129224
Fax 091-22-4168578
e-mail: webmaster@vaccinehaffkine.com
Website: www.vaccinehaffkine.com
 14. Indian Immunologicals Ltd

Indian Immunologicals Ltd. (IIL) was founded by National

Dairy Development Board (NDDB) in 1982 with the aim of
providing foot and mouth disease (FMD) vaccines to the
farmers at affordable prices. The technology for FMD vaccine
production was imported from M/s. Wellcome Foundation
Limited, UK. In 2003, it invested Rs. 50 crore to set up an
R&D facility in Hyderabad. IIL’s manufacturing facility in
Hyderabad has the capacity to produce 80 million trivalent
doses of FMD vaccine. It has WHO-GMP and ISO-9001:2000
certified plant in Ooty for the production of veterinary
vaccines. In 1989, IIL launched first tissue culture vaccine-
Raksharab.

In 2006 it achieved sales turnover of Rs. 100 crores and

became the 4th largest company in domestic animal
healthcare market. It had launched Elovac-B, r-DNA
Hepatitis-B vaccine, first vaccine from the Human Vaccine
manufacturing Plant in Hyderabad. It exports products to
the Gulf, Asian and African markets. In 2006, it entered into
collaboration with RxKinetix to develop thermostable
vaccines with improved stability at non-refrigerated
temperatures.

Its product portfolio in human vaccines includes MMR, DPT,

Hepatitis B, Rabies and Measles whereas its veterinary
vaccines include anti-rabies vaccine, canine vaccines, Foot
and Mouth (FMD) vaccine, bacterial vaccine and various
other combined vaccines.

Board of Directors

Dr. Amrita Patel, Chairman, IIL and NDDB

Mr. Deepak Tikku, Director, IIL and Managing Director of
NDDB
Mr. K V Balasubramaniam, Managing Director, IIL
Prof. G. Padmanaban, Director, IIL
Mr. A M M Sarma, Director, IIL
Dr. V A Srinivasan, Director (Research)

Contact Address:

Indian Immunologicals Ltd.

Road # 44, Jubilee Hills
Hyderabad - 500033
Andhra Pradesh, India

Tel: +91 40 23544585

+91 40 23544593
+91 9948298322
+91 9948298422
Fax: +91 40 23544007
E-mail: info@indimmune.com
Website: www.indimmune.com
 15. Krebs Biochem
Krebs Biochemicals & Industries Limited (KBIL) was founded
in 1991.It aims at developing biotech processes with
commercial application in the fields of medicine and
agriculture industry. In 1994 it went public to part finance
its fermentation technology project. In 2006, it achieved
sales turnover of Rs. 3,189 lacs and exports worth Rs. 1,352
lacs.

Krebs Biochem’s manufacturing units located at

Regadichelika Village, Nellore Dist., Andhra Pradesh produce
Pseudoephedrine, Ephedrine and other salts used for making
formulations for respiratory ailments, viz., cough, cold, etc.
It got USFDA and EDQM approval in 2003 and renewed its
WHO-GMP certificate in 2005
Board of Directors

Dr.M.Venkataratnam. IAS (retd), Chairman

Dr.B.Brahmaiah, IDBI nominee
Mrs.Sangeetha Sharma, Exim Bank nominee
Mr.M.Venkateswara Rao, APIDC nominee:
Dr.T.Kuchroo, Independent Directors
Mr.G.V.L.Prasad, Independent Directors
Mr.K.S.S.Prasad (small shareholders director) Independent
Directors
Dr. R T Ravi, Managing Director

Products:
Synthetic
Lavastatin
Simvastatin
I - Ephedrochiloride
d - Pseudoephedrine Hydrochloride
dl - Ephedrine Base
Herbal

Calcium Sennosides - 20% & 60%

Garcinia Combogia Powdered Extract
Capsaicin - 50/100

Intermediates
Crude Lovastatin
Simvastatin Ammonium Salt

Contact Address:

Krebs Biochemicals & Industries Limited

#401/402, 4th Floor,

Cyber Heights, Plot No 13,
Road No 2, Banjara Hills,
Hyderabad - 500033
Andhra Pradesh
India

Phones: +91-040-23540415
+91-040-23540416
+91-040-23541278
+91-040-55593175
Fax: +91-040-23540320

E-mail: marketing@krebsbiochem.com

Website: www.krebsbiochem.com
 16. Metahelix Life Sciences
With a venture capital of US$ 1.5 million, Metahelix Life
Sciences Private Limited was founded by five scientists, viz.
K. K. Narayanan, Gautham Nadig, Suri Venkatachalam,
Ganesh Kishore, and Himadri Pakrasi in December 2000 at
Bangalore, India. It was established with the aim of gene
discovery for agronomic and nutritional enhancement of food
and commercial crops.

Scientific consulting and contract research in life science

informatics and functional genomics are its areas of
specialization. It also provides algorithm design and
software development for various applications in
bioinformatics. Its headquarters is in Bangalore, India. It
has employee strength of about 40 scientists.

In 2003, Metahelix had signed a four-year genomic research

agreement with ViaLactia BioSciences (NZ) Ltd., a dairy
biotechnology company. The research aims at providing
functional validation of a number of genes from pasture
plants. The programme has the potential to produce
improved plant varieties of pasture and crop plants.
Board of Directors K. K. Narayanan (Managing Director)
Gautham Nadig (Director)
Ravi Krishna (President -Seeds)
Vasudeva Rao (President -Ag Technologies)

S.n Experienc Job

Job Title Qualifications
o e Responsibility
The
Research M.Sc ( Plant
incumbent
Associate/Juni Breeding &
1 1-3 yrs shall be
or Scientist Genetics)/
responsible
(Genomics) Biotechnology
for plant
 tissue culture
and
transformatio
n works
To assist
Cotton
M.Sc in Plant Breeder
Assistant
Breeding and in cotton
2 Breeder(Cotto
Genetics. PhD breeding
n)
preferred activities
of the
company
UG - B.Sc -
Agriculture, To assist the
PG - M.Sc - Rice breeder
Assistant Agriculture, in rice
3 3-5 years
Breeder(Rice) PPG - breeding
Ph.D/Doctorat activities of
e- the company
Agriculture
To assist the
Crop Lead in
Maize
UG - B.Sc - Breeding
Agriculture, activities.
PG - M.Sc - Should have
Assistant Agriculture, hands on
4 3 to 5 yrs
Breeder(Maize PPG - experience
Ph.D/Doctorat for a period
e- of 2 to 5
Agriculture years in
Maize
Breeding
activities.
Trainees in UG - B.Sc -
5 0-1 years
Plant Breeding Agriculture,
 PG - M.Sc -
Agriculture,
PPG -
Ph.D/Doctorat
e - any
specialization
Minimum
2 to 4
years
experienc
UG - B.Sc -
e in
Agriculture,
Parent
PG - M.Sc - Responsible
seed
Agriculture, for Parent
Parent Seeds productio
6 PPG - Any seeds
Officers n
Ph.D / production
activities
Doctorate / activities.
in reputed
M.Phil. - Any
Agri-
Specialization
biotech
Seed
Companie
s
Responsible
UG - B.Sc -
for Okra
Agriculture,
Breeding
PG - M.Sc -
activity and
Agriculture,
7 Okra Breeder 5-8 years to develop
PPG – Ph.D /
commercial
Doctorate /
production of
M.Phil. Not
high quality
Required
Okra hybrids.
Contact Information for Job Openings:

Name Mr. B Girish Kumar

Telephone 9880341522, 91-080-7870236, 7836086
Fax: 7836084
Website http://www.meta-helix.com
Products:
Genomics
Plant Transformation and Trait Development
Functional Genomics
Genetic Purity Testing
Marker Development

Computational Biology
Protein Informatics
Protein Structure Modeling
Modeling and Simulation of Cellular Processes

Contact Address:
Metahelix Life Sciences Pvt. Ltd
Plot No. 3, KIADB 4th Phase,
Bommasandra Industrial Area,
Bangalore 560 099
Tel: +91-80-783 6086
Fax: +91-80-783 6084
email: info@meta-helix.com
Website: www.meta-helix.com
 17. Wipro Biomed
Wipro Biomed, formed in 1988, is a US$ 2 billion biomedical
business division of Wipro Limited. It has 3 businesses:
Diagnostics System Group, Life Science Group and Medical
Systems Group. It has 7 offices and employee strength of
about 80.

Wipro Biomed has networked and interconnected offices so

as to have flawless communication with its customers. It has
45 distribution centres and more than 1500 customers. It
has 8 teams in diagnostics and research and 23 support
teams. It offers services in life sciences, clinical diagnostics
and medical systems.

With a growth rate of 18.5%, Wipro Biomed had achieved

business of Rs. 61.8 crore in 2005. In 2006, it entered into
strategic alliance with CiPhergen BioSystems Inc. to market
ProteinChip Systems and Solutions, products of Ciphergen,
in India, Bangladesh, Sri Lanka and Nepal.

Board of Directors

Varsha Anand, Vice President

Diwakar Virnave, Head - Services and Medical divisions

Dipak Banerjee, Head - Strategic Accounts (Diagnostics

Division)

Rajnish Bharti, Head - Life Science Business (Lab)

Bhupendra Chaudhary, Business Head (Diagnostics

Group)

Joy Joseph, Chief Scientific Officer & Business Manager

Specialty Products
Contact Address:
Wipro Biomed, C Block,
Ground Floor, Sarjapur Campus- 1
Doddakannelli, Sarjapur Road,
Bangalore – 560035
Phone: 28440011/ 28440376
Fax: 080- 28440367
Email: bhupendra.chaudhary@wipro.com
Website: www.wiprobiomed.in